Drugs / ORIC-101
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials · 1 missed | ||||||
| Phase 1 | NCT04033328 | Oct 2019 → Nov 2022 | prostate neoplasm | ORIC Pharmaceuticals | Terminated | Missed primary |
| Phase 1 | NCT03928314 | May 2019 → Sep 2022 | cancer | ORIC Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT03835637 | Mar → Jul 2018 | — | ORIC Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT03324555 | Oct → Dec 2017 | — | ORIC Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05652920 | Dec 2022 → Dec 2026 expected | hepatocellular carcinoma | OriCell Therapeutics Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORIC-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03928314 ↗ |
| Action | Inhibit | “oral GR antagonist ORIC-101” NCT03835637 ↗ |
| Modality | Small molecule | “ORIC-101 is a small molecule GR antagonist” NCT03928314 ↗ |
| Route | Oral | “ORIC-101 oral suspension” NCT03324555 ↗ |
| Target | GPC3 | “GPC3-directed chimeric antigen receptor modified T cells” NCT05652920 ↗ |